Bertil Uggla

Articles in journals

• Kättström, M. , Uggla, B. , Tina, E. , Kimby, E. , Norén, T. & Athlin, S. (2023). Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. Vaccine, 41 (9), 3128-3136.
• Österroos, A. , Maia, T. , Eriksson, A. , Jädersten, M. , Lazarevic, V. , Wennström, L. , Antunovic, P. , Cammenga, J. & et al. (2022). A risk score based on real-world data to predict early death in acute promyelocytic leukemia. Haematologica, 107 (7), 1528-1537.
• Orsmark-Pietras, C. , Landberg, N. , Lorenz, F. , Uggla, B. , Höglund, M. , Lehmann, S. , Derolf, Å. , Deneberg, S. & et al. (2021). Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. Genes, Chromosomes and Cancer, 60 (6), 426-433.
• Lidén, M. , Adrian, D. , Widell, J. , Uggla, B. & Thunberg, P. (2021). Quantitative T2* imaging of iron overload in a non-dedicated center - Normal variation, repeatability and reader variation. European journal of radiology open, 8.
• Kozlowski, P. , Kameran Behnam, K. , Uggla, B. & Åström, M. (2020). Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. European Journal of Haematology, 104 (6), 588-593.
• Derolf, Å. , Juliusson, G. , Benson, L. , Fløisand, Y. , Lazarevic, V. , Antunovic, P. , Möllgård, L. , Lehmann, S. & et al. (2020). Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. British Journal of Haematology, 188 (1), 187-191.
• Österroos, A. , Eriksson, A. , Antunovic, P. , Cammenga, J. , Deneberg, S. , Lazarevic, V. , Lorenz, F. , Möllgård, L. & et al. (2020). Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years. British Journal of Haematology, 189 (1), e13-e16.
• Vaht, K. , Göransson, M. , Carlson, K. , Isaksson, C. , Lenhoff, S. , Sandstedt, A. , Uggla, B. , Winiarski, J. & et al. (2019). High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. Biology of blood and marrow transplantation, 25 (10), 1970-1974.
• Vaht, K. , Göransson, M. , Carlson, K. , Isaksson, C. , Lenhoff, S. , Sandstedt, A. , Uggla, B. , Winiarski, J. & et al. (2018). Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia: A Swedish nationwide cohort study. European Journal of Haematology, 100 (6), 613-620.
• Lehmann, S. , Deneberg, S. , Antunovic, P. , Rangert-Derolf, Å. , Garelius, H. K. G. , Lazarevic, V. L. J. , Myhr-Eriksson, K. , Möllgård, L. & et al. (2017). Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia, 31 (6), 1457-1459.
• Vaht, K. , Göransson, M. , Carlson, K. , Isaksson, C. , Lenhoff, S. , Sandstedt, A. , Uggla, B. , Winiarski, J. & et al. (2017). Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica, 102 (10), 1683-1690.
• Lazarevic, V. L. , Rosso, A. , Juliusson, G. , Antunovic, P. , Derolf, Å. R. , Deneberg, S. , Möllgård, L. , Uggla, B. & et al. (2017). Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. European Journal of Haematology, 98 (5), 493-500.
• Juliusson, G. J. , Abrahamsson, J. , Lazarevic, V. L. J. , Antunovic, P. , Derolf, Å. R. , Garelius, H. K. G. , Lehmann, S. , Myhr-Eriksson, K. & et al. (2017). Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia, 31 (3), 728-731.
• Hulegardh, E. , Nilsson, C. , Lazarevic, V. , Garelius, H. , Antunovic, P. , Rangert Derolf, A. , Mollgard, L. , Uggla, B. & et al. (2015). Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry. American Journal of Hematology, 90 (3), 208-214.
• Lazarevic, V. , Hörstedt, A. , Johansson, B. , Antunovic, P. , Billström, R. , Derolf, A. , Lehmann, S. , Möllgård, L. & et al. (2015). Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. European Journal of Haematology, 94 (5), 419-423.
• Lazarevic, V. , Rosso, A. , Juliusson, G. , Antunovic, P. , Rangert-Derolf, A. , Lehmann, S. , Mollgard, L. , Uggla, B. & et al. (2015). Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia. American Journal of Hematology, 90 (9), 800-805.
• Uggla, B. & Nilsson, T. (2015). Whole blood viscosity in plasma cell dyscrasias. Clinical Biochemistry, 48 (3), 122-124.
• Burman, J. , Iacobaeus, E. , Svenningsson, A. , Lycke, J. , Gunnarsson, M. , Nilsson, P. , Vrethem, M. , Fredrikson, S. & et al. (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 85 (10), 1116-1121.
• Mulligan, S. P. , Karlsson, K. , Strömberg, M. , Jønsson, V. , Gill, D. , Hammerström, J. , Hertzberg, M. , McLennan, R. & et al. (2014). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia and Lymphoma, 55 (12), 2769-2777.
• Lazarevic, V. , Hörstedt, A. , Johansson, B. , Antunovic, P. , Billström, R. , Derolf, A. , Hulegårdh, E. , Lehmann, S. & et al. (2014). Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer Journal, 4 (2).
• Ekbäck, M. [. & Uggla, B. (2012). Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab. Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, 36 (8), E190-E191.
• Lehmann, S. , Bykov, V. , Ali, D. , Andrén, O. , Cherif, H. , Tidefelt, U. , Uggla, B. , Yachnin, J. & et al. (2012). Targeting p53 in vivo: a first-in-man study with the p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. Journal of Clinical Oncology, 30 (29), 3633-3639.
• Deneberg, S. , Guardiola, P. , Lennartsson, A. , Qu, Y. , Gaidzik, V. E. , Blanchet, O. , Karimi, M. , Bengtzén, S. & et al. (2011). Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood, 118 (20), 5573-5582.
• Prenkert, M. , Uggla, B. , Tidefelt, U. & Strid, H. (2010). CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells. Anticancer Research, 30 (10), 4157-61.
• Prenkert, M. , Uggla, B. , Tina, E. , Tidefelt, U. & Strid, H. (2009). Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells. Anticancer Research, 29 (10), 4071-4076.
• Uggla, B. , Tina, E. , Nahi, H. , Paul, C. , Höglund, M. , Sirsjö, A. & Tidefelt, U. (2007). Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. International Journal of Oncology, 31 (1), 153-160.
• Uggla, B. , Ståhl, E. , Wågsäter, D. , Paul, C. , Karlsson, M. G. , Sirsjö, A. & Tidefelt, U. (2005). BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, 29 (2), 141-146.
• Uggla, B. , Möllgård, L. , Ståhl, E. , Mossberg, L. M. , Karlsson, M. G. , Paul, C. & Tidefelt, U. (2001). Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells. Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, 25 (11), 961-966.

Conference papers

• Mattsson, A. , Sylvan, S. , Mulder, T. , Axelsson, P. , Ellin, F. , Lewerin, C. , Uggla, B. , Österborg, A. & et al. (2020). Real-world data on the PI3Kd inhibitor idelalisib in relapsed/refractory CLL patients treated in Sweden. In:  Leukemia and Lymphoma. Paper presented at XVIII International Workshop on Chronic Lymphocytic Leukemia, Edinburgh, UK, September 20-23, 2019. (pp. 66-67). Taylor & Francis.

Manuscripts

• Prenkert, M. , Uggla, B. , Tidefelt, U. & Strid, H. CRIM1 is expressed at higher levels in drug resistant than in drug sensitive myeloid leukemia HL60 cells.